FDA RMAT Designations Reach 162 Total: Rocket Pharmaceuticals and CRISPR Therapeutics Lead

July 5, 2026

BioInformant USA

Overview

The FDA’s publicly announced Regenerative Medicine Advanced Therapy (RMAT) designations have reached a total of 162, with approximately half of all RMAT applications being approved, according to BioInformant data. This trend indicates a mature pipeline of innovative regenerative medicine products leveraging accelerated regulatory pathways. Notably, Rocket Pharmaceuticals holds 5 RMAT designations and CRISPR Therapeutics holds 4, demonstrating leadership in rare diseases and oncology. RMAT designation serves as a strong early signal for transformative next-generation therapies, making it a critical indicator for biopharma investors and developers.

In Depth

Key Findings

The total number of Regenerative Medicine Advanced Therapy (RMAT) designations publicly announced by the U.S. FDA has reached 162, with approximately 50% of RMAT applications being granted. This insight, derived from BioInformant’s latest database analysis, clearly indicates the rapid growth of the cell and gene therapy product pipeline and its effective utilization of expedited regulatory pathways for market entry.

Technical / Clinical Details

RMAT designation is granted to regenerative medicine products intended to treat, modify, or cure serious or life-threatening diseases. This designation allows the FDA to provide intensive guidance to developers from early stages and apply accelerated review mechanisms, such as rolling review and accelerated approval. Data show that Rocket Pharmaceuticals is among the companies with the most RMAT designations, holding five for its gene therapy pipeline targeting genetic diseases. CRISPR Therapeutics, a leader in gene editing technology, also boasts four RMAT designations, underscoring the progress and recognition of its innovative therapies. These designations suggest that the therapies under development by these companies are highly likely to offer clinically significant improvements over existing treatments.

Background & Context

Introduced in 2016 by the 21st Century Cures Act, the RMAT designation aims to accelerate innovation in the regenerative medicine and cell and gene therapy sectors. Compared to traditional drug approval processes, RMAT enhances collaboration with regulatory authorities from the development phase based on early clinical data, potentially significantly reducing the time it takes for products to reach patients. This framework provides incentives for development, particularly in areas of high unmet medical need such as rare diseases and cancer. The FDA’s public list of RMAT designations serves as a valuable resource for identifying industry trends and pinpointing which companies and technologies hold the potential for the next major breakthroughs.

Strategic Significance & Outlook

The continuous increase in RMAT designations signals vibrant research and development activity in regenerative medicine, with more innovative therapies progressing through clinical trials toward approval. It is anticipated that clinical trial results for RMAT-designated products will be published and subsequently launched into the market, significantly improving the lives of many patients. Furthermore, the commercial success of RMAT-designated products is expected to attract further investment, accelerating the growth of the entire sector. Early engagement between regulatory bodies and developers will remain an essential component for efficiently advancing the development of complex regenerative medicine products in the future.

Source: https://bioinformant.com/product/rmat-designations/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.